Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Obecabtagene autoleucel (obe-cel), Obecabtagene autoleucel, AUTO1
obe-cel (AUTO1) · 5 trials · 5 indications
CRR is a composite endpoint
Percentage of patients receiving obe-cel who experience dose-limiting toxicities (DLTs)
Adverse event (AE) type, frequency, severity, and relationship with obe-cel and lymphodepletion of AEs
| Arm | Type | Description |
|---|---|---|
| Obe-cel | EXPERIMENTAL | - |
| AUTO1 | EXPERIMENTAL | - |
| Obecabtagene autoleucel (obe-cel) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Obecabtagene autoleucel | BIOLOGICAL | Obecabtagene autoleucel (obe-cel) given as a single infusion |
| AUTO1 | BIOLOGICAL | Following pre-conditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with a total target dose of 410E+6 of CD19-positive CAR T cells as a split dose on Day 1 and on Day 10 (±2 days). |
| Obecabtagene autoleucel (obe-cel) | BIOLOGICAL | Obecabtagene autoleucel (obe-cel) given as a single infusion. |
Inclusion Criteria: * Willing and able to give written informed consent for participation in the study or written informed consent signed by a legal guardian or representative * Ability and willingness to adhere to protocol's Schedule of Activities and other requirements * Participants must be 12 t...
Top 18 of 19 competitors
Obe-cel is an investigational CD19-targeted CAR T cell therapy developed by Autolus Therapeutics plc (ticker AUTL). It is being studied in B cell acute lymphoblastic leukemia and in autoimmune conditions including systemic lupus erythematosus, lupus nephritis, and progressive multiple sclerosis. It is also known as obecabtagene autoleucel, or AUTO1.
Obe-cel targets CD19, a B cell surface protein. Because CD19 is expressed on B cells, the therapy is directed at B cell populations in both hematologic malignancies such as B cell acute lymphoblastic leukemia and in autoimmune diseases where B cells contribute to disease activity, including lupus nephritis and systemic lupus erythematosus.
Obe-cel is being developed by Autolus Therapeutics plc, which trades under the ticker AUTL. The company is running clinical programs for obecabtagene autoleucel across relapsed or refractory B cell acute lymphoblastic leukemia and several autoimmune indications, including systemic lupus erythematosus, lupus nephritis, and progressive multiple sclerosis.
Obe-cel is investigational and in clinical development. Its lupus nephritis program is in Phase 2, while studies in progressive multiple sclerosis, systemic lupus erythematosus, and pediatric relapsed or refractory B cell acute lymphoblastic leukemia are Phase 1. Obe-cel has not been established as approved for these uses in the trials described here.
Obe-cel trials include NCT07053800, a Phase 2 study in severe refractory systemic lupus erythematosus with active lupus nephritis, and NCT07139743, a Phase 1 study in refractory progressive multiple sclerosis. Phase 1 studies also include NCT06333483 in severe refractory systemic lupus erythematosus and NCT06173518 in pediatric relapsed or refractory B cell acute lymphoblastic leukemia and aggressive mature B cell non-Hodgkin lymphoma.
Yes. Obe-cel is the short name for obecabtagene autoleucel, which is also referred to by the code AUTO1. All three names refer to the same CD19-targeted CAR T cell therapy developed by Autolus Therapeutics plc (ticker AUTL) and studied across B cell acute lymphoblastic leukemia and autoimmune indications.